background
may
import
case
middl
east
respiratori
syndrom
coronaviru
merscov
infect
occur
china
rapid
reliabl
diagnosi
suspect
case
necessari
object
extern
qualiti
assess
eqa
program
molecular
detect
merscov
organ
nation
center
clinic
laboratori
nccl
studi
design
viruslik
particl
vlp
encapsul
specif
rna
sequenc
merscov
prepar
posit
specimen
assess
panel
compris
three
neg
seven
posit
sampl
differ
concentr
vlp
distribut
laboratori
provinc
municip
autonom
region
molecular
detect
result
among
receiv
data
set
three
employ
inhousedevelop
realtim
reversetranscript
polymeras
chain
reaction
rrtpcr
assay
other
appli
variou
commerci
rrtpcr
kit
overal
major
laboratori
could
achiev
accuraci
merscov
detect
three
laboratori
still
room
improv
consequ
neg
sampl
identifi
correctli
reach
specif
falseneg
rate
falseneg
result
obtain
sampl
rel
low
concentr
indic
urgent
need
improv
detect
weakposit
specimen
conclus
major
particip
possess
reliabl
diagnost
capac
detect
merscov
moreov
eqa
indispens
help
enhanc
diagnost
capabl
surveil
merscov
infect
allow
comparison
result
among
differ
laboratori
sinc
discoveri
middl
east
respiratori
syndrom
coronaviru
merscov
saudi
arabia
laboratoryconfirm
human
case
includ
death
mortal
rate
merscov
kind
novel
envelop
viru
singlestrand
positivesens
rna
genom
caus
sever
respiratori
complic
renal
failur
infect
patient
although
merscov
infect
occur
middl
east
case
report
europ
north
america
asia
peopl
travel
middl
east
contact
sinc
may
republ
korea
newli
affect
caus
largest
outbreak
merscov
outsid
arabian
peninsula
highlight
import
surveil
system
prevent
spread
simultan
china
increas
effort
detect
merscov
import
case
mer
korea
threat
public
health
henc
rapid
effect
diagnosi
infecti
agent
crucial
time
control
manag
diseas
laboratori
detect
merscov
base
molecular
techniqu
commonli
use
approach
realtim
reversetranscript
polymeras
chain
reaction
rrtpcr
essenti
indispens
method
laboratori
molecular
diagnost
recent
world
health
organ
publish
updat
interim
guidanc
laboratori
test
merscov
three
assay
diagnos
merscov
http
elsevi
bv
right
reserv
infect
develop
base
detect
specif
region
viral
rna
rrtpcr
test
includ
assay
target
upstream
envelop
gene
upe
highli
sensit
recommend
laboratori
screen
follow
confirm
assay
target
either
open
read
frame
orf
orf
meanwhil
unit
state
center
diseas
control
prevent
us
cdc
develop
rrtpcr
assay
target
nucleocapsid
n
gene
merscov
complement
upe
orf
assay
screen
confirm
addit
confirm
screen
test
aid
partial
sequenc
rnadepend
rna
polymeras
rdrp
n
gene
sinc
first
case
mer
identifi
chines
cdc
publish
provid
primerprob
set
rapid
molecular
diagnosi
suspect
infect
well
sever
commerci
kit
manufactur
howev
divers
nucleic
acid
extract
techniqu
detect
method
instrument
commerci
assay
use
dispar
individu
oper
may
caus
variat
evalu
laboratori
perform
therefor
urgent
need
qualiti
assur
diagnost
could
make
result
obtain
differ
laboratori
compar
extern
qualiti
assess
eqa
import
part
laboratori
qualiti
manag
improv
nationwid
eqa
implement
nation
center
clinic
laboratori
nccl
evalu
merscov
diagnost
capabl
laboratori
within
chines
mainland
two
target
segment
nucleotid
sequenc
merscov
genom
genbank
access
synthes
separ
first
bp
consist
part
upe
gene
bp
encompass
part
orf
orf
n
rdrp
gene
chimer
sequenc
amplifi
primer
list
tabl
gelpurifi
separ
subclon
kpn
ipvu
kpn
ipac
site
vector
form
recombin
plasmid
respect
two
kind
viruslik
particl
vlp
packag
specif
sequenc
merscov
express
purifi
accord
previous
publish
protocol
laboratori
identifi
transmiss
electron
microscopi
tem
enzymat
digest
test
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
rtpcr
stabil
two
type
merscov
vlp
evalu
dulbecco
modifi
eagl
medium
dmem
gibco
usa
variou
condit
firstli
rna
vlp
extract
use
qiaamp
viral
rna
mini
kit
qiagen
germani
quantifi
use
absorbancebas
nucleic
acid
quantif
method
nanodrop
thermo
concentr
sampl
calcul
use
formula
copiesmol
gml
mw
gmol
copiesml
kind
quantifi
vlp
dilut
dmem
order
obtain
sampl
two
concentr
sampl
incub
c
c
c
defin
period
time
point
store
c
sampl
collect
sampl
assess
duplic
use
merscov
rrtpcr
kit
bioperfectu
technolog
jiangsu
china
dmem
use
neg
control
run
code
panel
n
eqa
consist
three
neg
seven
posit
sampl
rang
copiesml
accord
detect
rna
concentr
clinic
respiratori
specimen
posit
sampl
obtain
appropri
dilut
mix
two
kind
merscov
vlp
tabl
among
seven
posit
sampl
lowest
concentr
prepar
determin
detect
limit
variou
commerci
kit
detect
capabl
differ
laboratori
two
replic
specimen
prepar
evalu
repeat
particip
oper
dmem
use
neg
sampl
dilut
buffer
posit
one
addit
one
neg
sampl
contain
measl
viru
mv
hepat
c
viru
hcv
vlp
use
test
whether
merscov
detect
could
obscur
presenc
virus
dispatch
sampl
assess
identifi
three
time
test
sampl
ship
ice
particip
laboratori
along
instruct
particip
ask
detect
merscov
use
routin
oper
procedur
detail
qualit
result
threshold
cycl
ct
valu
sampl
inform
rna
extract
detect
method
instrument
use
time
point
begin
merscov
molecular
detect
record
result
classifi
compet
correct
respons
accept
incorrect
result
improv
incorrect
result
statist
analys
perform
use
spss
version
sensit
among
differ
group
compar
appli
pearson
chisquar
test
fisher
exact
test
appropri
p
valu
regard
statist
signific
merscov
vlp
construct
express
success
valid
sequenc
seri
experi
fig
shown
fig
diamet
merscov
vlp
nm
confirm
tem
protein
band
could
seen
conduct
sdspage
analysi
fig
digest
rnase
dnase
h
c
singl
band
kb
length
visibl
use
agaros
gel
electrophoresi
ethidium
bromid
fig
rtpcr
appli
confirm
success
packag
target
sequenc
fig
stabil
evalu
reveal
merscov
vlp
could
stabl
least
two
week
c
one
month
c
two
month
c
fig
sampl
panel
assess
use
differ
commerci
kit
distribut
test
could
confirm
posit
neg
result
success
total
laboratori
provinc
municip
autonom
region
particip
eqa
merscov
molecular
detect
among
laboratori
provinci
municip
cdc
china
laboratori
involv
amplifi
sequenc
design
hospit
suspect
merscov
infect
nine
commerci
kit
manufactur
fig
addit
half
particip
establish
merscov
molecular
detect
project
sinc
nucleic
acid
extract
variou
commerci
kit
appli
select
laboratori
fig
among
particip
chose
spin
column
method
particip
chose
magnet
bead
method
one
use
trizol
method
extract
rna
manual
extract
prefer
agenc
other
appli
autom
nucleic
acid
extractor
howev
except
three
particip
employ
inhousedevelop
rrtpcr
assay
particip
appli
commerci
avail
rrtpcr
kit
fig
complet
data
set
perform
found
compet
analys
perform
seven
particip
classifi
accept
three
laboratori
includ
improv
group
fig
result
suggest
differ
test
perform
among
cdc
design
hospit
manufactur
p
total
result
target
upe
orf
gene
return
incorrectli
report
laboratori
falseneg
tabl
sensit
upe
orf
detect
respect
suggest
statist
differ
p
neg
sampl
correctli
identifi
reach
c
inhous
inhousedevelop
rrtpcr
assay
merscov
detect
recommend
chines
cdc
specif
particularli
mixtur
virus
sampl
interfer
detect
merscov
next
evalu
perform
differ
assay
total
sensit
specif
respect
tabl
commerci
avail
assay
bioperfectu
technolog
wide
use
particip
sensit
differ
compet
among
first
six
commerci
assay
tabl
inhousedevelop
assay
p
howev
commerci
assay
tianlong
biotech
co
ltd
use
two
agenc
sensit
laboratori
use
return
five
falseneg
result
orf
gene
total
classifi
improv
group
three
commerci
assay
roch
diagnost
shanghai
ltd
sansur
biotech
co
ltd
kinghawk
pharmaceut
co
ltd
appli
one
laboratori
sampl
correctli
verifi
inhousedevelop
assay
recommend
chines
cdc
produc
accur
result
three
particip
achiev
compet
outcom
addit
result
n
gene
return
nine
laboratori
includ
three
falseposit
result
report
two
agenc
tabl
sinc
occurr
import
case
mer
china
diagnost
procedur
merscov
develop
chines
cdc
accord
employ
first
appear
china
quit
import
carri
rapid
diagnosi
provid
reliabl
detect
result
studi
first
eqa
program
evalu
laboratori
perform
capabl
merscov
molecular
diagnosi
china
result
eqa
show
major
laboratori
could
achiev
accuraci
merscov
detect
particularli
neg
sampl
panel
identifi
correctli
reach
specif
rna
concentr
copiesml
close
clinic
specimen
obtain
lower
respiratori
tract
outcom
fail
detect
weakposit
sampl
thu
circumst
falseneg
result
investig
issu
sensit
clinic
work
may
caus
delay
treatment
infect
patient
potenti
spread
epidem
manag
intern
control
advis
nucleic
acid
extract
oper
standard
emphas
observ
signific
differ
sensit
upe
orf
detect
furthermor
similar
phenomenon
found
three
sampl
rel
low
rna
concentr
suggest
assay
target
upe
gene
sensit
target
orf
accord
report
studi
clarifi
fact
upe
gene
higher
sensit
appropri
screen
assay
eqa
wide
rang
commerci
assay
employ
among
assay
bioperfectu
technolog
wide
use
particip
reach
sensit
howev
two
laboratori
use
commerci
assay
tianlong
biotech
co
ltd
report
five
falseneg
result
orf
gene
classifi
improv
group
specif
one
particip
chose
tiangen
kit
appli
spin
column
method
manual
use
tianlong
kit
appli
magnet
bead
method
automat
extract
rna
moreov
sensit
orf
detect
ten
assay
tabl
accept
suggest
merscov
sequenc
vlp
met
requir
molecular
detect
could
conduct
indepth
analysi
owe
limit
number
user
implement
followup
evalu
perform
two
particip
laboratori
practic
optim
extern
qualiti
manag
requir
previou
intern
eqa
molecular
diagnost
merscov
posit
cell
cultur
supernat
contain
viru
inactiv
use
valid
specimen
result
high
varianc
receiv
differ
laboratori
owe
larg
lack
intern
nucleic
acid
test
nat
standard
comparison
vlp
encapsul
specif
sequenc
merscov
rna
use
studi
surrog
exhibit
superior
advantag
noninfecti
nucleas
resist
stabl
safe
transport
moreov
rna
vlp
quantifi
result
credibl
compar
stabil
analys
suggest
merscov
vlp
could
stabl
least
two
week
c
one
month
c
two
month
c
fig
conclus
overal
perform
first
eqa
program
merscov
detect
china
indic
major
particip
laboratori
compet
detect
emerg
viru
show
robust
capabl
confirm
result
nevertheless
poor
score
exhibit
small
number
particip
suggest
seriou
need
improv
laboratori
practic
standard
oper
procedur
strengthen
daili
qualiti
manag
eqa
help
improv
diagnost
capabl
laboratori
find
best
solut
solv
exist
problem
low
detect
sensit
sampl
lower
viral
concentr
thu
wider
eqa
merscov
molecular
detect
incorpor
laboratori
human
coronavirus
expect
plan
conduct
futur
